classifying xylazine as a schedule III controlled drug.
Summary
SB 465 classifies xylazine as a Schedule III controlled drug under New Hampshire’s Controlled Drug Act. The bill creates a new statutory section directing that xylazine be scheduled by law, rather than through the Department of Health and Human Services’ normal rulemaking process. It also includes explicit exceptions for licensed veterinarians, allowing them to dispense, prescribe, or administer xylazine to nonhuman species when the use is approved or otherwise permissible under federal law.
The bill is set to take effect on January 1, 2027. Its practical effect is to place xylazine under the state’s controlled-substance framework, which can affect how the drug is possessed, distributed, prescribed, and enforced against in non-veterinary contexts. Because the bill changes criminal-drug scheduling, the fiscal note anticipates possible but indeterminable impacts on judicial and correctional systems, while estimating no direct revenue change and no appropriations.
Impact
SB 465 amends RSA 318-B by adding xylazine to Schedule III, overriding the usual administrative scheduling process in RSA 318-B:1-a. This changes state controlled-substance law by making xylazine subject to the regulatory and enforcement provisions that apply to Schedule III drugs, while preserving lawful veterinary uses for nonhuman species under federal drug law. The bill may indirectly affect law enforcement, prosecution, courts, probation, incarceration, and related county and local costs, though the fiscal note does not quantify those effects.
Sentiment
The available context suggests generally supportive or at least noncontroversial treatment of the bill, with bipartisan sponsorship and no recorded votes or committee transcript opposition in the materials provided. The bill’s framing as a controlled-drug scheduling measure and its explicit veterinary carve-out indicate an effort to address public-safety concerns while preserving legitimate animal-health uses. Because no committee discussion or roll-call vote is included, there is no documented formal dissent in the provided record.
Contention
The main policy issue is the decision to classify xylazine directly in statute rather than leaving scheduling to agency rulemaking, which can raise questions about flexibility and administrative process. A second point of concern is balancing enforcement against misuse of xylazine with continued access for veterinarians treating nonhuman species. The fiscal note also flags uncertainty about downstream judicial and correctional costs, which may be a concern for agencies and local governments even though no specific dollar impact is estimated.
Criminalizing multiple forms of exposing children to controlled substances and allowing law enforcement to take a child into protective custody for screening and testing in an instance of suspected or actual criminal exposure to controlled substances.
Relative to the penalty for certain fentanyl-related offenses; relative to establishing a mandatory minimum sentence for the crime of distribution of a controlled drug with death resulting; and relative to amending the penalties for the possession and use of a quantity of psilocybin for persons 18 years of age or older.